BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially av
04 Apr 2019
BioLargo - Guidance: Odor-No-More break-even by YE19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BioLargo - Guidance: Odor-No-More break-even by YE19
BioLargo reported record revenue in 2018 of $1.4m, more than doubling from the previous year, with the majority of this revenue attributable to Odor-No-More at $1.1m. Odor-No-More continues to improve its margins and is expected to break even by the end of 2019. Moreover, it expects to provide the data needed to complete a 510(k) for its Clyra wound care product in six months, with a spin-off planned for around the end of 2019, and for the Advanced Oxidation System (AOS) to be commercially av